E. coli Outbreak in Canada
Provides Study Opportunity for Company
CALGARY, CANADA-An outbreak of E. coli has provided an unique opportunity for a pharmaceutical company developing a drug to treat the bacteria. Canadian-based Synsorb Biotech was asked to supply its Synsorb Pk(R) to hospitals in Walkerton, Ontario, where hundreds of residents have become ill after drinking contaminated water. The Canadian Health Authorities issued approval for emergency use of the treatment designed to prevent serious complications associated with verotoxigenic E. coli (VTEC) infections. Synsorb Pk(R) attaches to the bacteria's toxins and neutralizes them allowing safe passage through the digestive tract. According to Synsorb, approximately 10% of the patients who become infected with E. coli develop Hemolytic Uremic Syndrome (HUS), a potentially deadly kidney disease. Consequently, the treatment has been given fast track product designation by the US Food and Drug Administration (FDA). Synsorb has been delayed producing clinical trial results because large-scale outbreaks are rare.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
